Menu closed

Login / Register
Medical Home
Science
Medical Information
Medical Education
Contact Us

You are now leaving the LillyMedical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.

Oncology Journal Publications

This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979). For our publication linking statement click here.

For all other requests, please visit our Contact Lilly services.

Cyramza^® (ramucirumab)

Full Prescribing Information

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

Published Date: November 30, 2024

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

Published Date: December 19, 2023

Bayesian Survival Extrapolation for Cost effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancer

Published Date: October 16, 2023

Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study).

Published Date: September 7, 2023

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR mutation-positive metastatic NSCLC: Exploratory analysis of next-generation sequencing results

Published Date: August 1, 2023

Efficacy and tolerability of ramucirumab plus erlotinib in Taiwanese patients with untreated, epidermal growth factor receptor-mutated stage IV non-small-cell lung cancer in the RELAY study

Published Date: June 17, 2023

RELAY, Ramucirumab plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association between TP53 Status and Clinical Outcome

Published Date: March 27, 2023

RELAY, Ramucirumab plus Erlotinib versus Placebo plus Erlotinib in Untreated EGFR-Mutated Metastatic Non-Small Cell Lung Cancer: Exposure-Response Relationship

Published Date: July 16, 2022

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

Published Date: March 28, 2022

RELAY: Clinical and Next-Generation Sequencing Analyses of Ex19del and Ex21L858R Mutation Subgroups in Untreated, EGFR-Mutated, Metastatic Non-small Cell Lung Cancer

Published Date: January 3, 2022

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, epidermal growth factor receptor mutation-positive, metastatic non-small cell lung cancer: long-term toxicity and resource use

Published Date: January 3, 2022

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.

Published Date: June 29, 2021

Evaluating alternative ramucirumab doses as single agent or with paclitaxel in second-line treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: results from 2 randomized, open-label, phase II studies

Published Date: February 24, 2022

RELAY: Safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC

Published Date: November 4, 2025

RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

Published Date: September 26, 2025

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

Published Date: November 30, 2024

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

Published Date: December 19, 2023

Bayesian Survival Extrapolation for Cost effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancer

Published Date: October 16, 2023

Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study).

Published Date: September 7, 2023

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR mutation-positive metastatic NSCLC: Exploratory analysis of next-generation sequencing results

Published Date: August 1, 2023

Efficacy and tolerability of ramucirumab plus erlotinib in Taiwanese patients with untreated, epidermal growth factor receptor-mutated stage IV non-small-cell lung cancer in the RELAY study

Published Date: June 17, 2023

RELAY, Ramucirumab plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association between TP53 Status and Clinical Outcome

Published Date: March 27, 2023

Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study

Published Date: March 20, 2023

Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study.

Published Date: October 10, 2022

Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: Final results from an expansion cohort of the phase 3 REACH-2 study

Published Date: October 6, 2022

RELAY, Ramucirumab plus Erlotinib versus Placebo plus Erlotinib in Untreated EGFR-Mutated Metastatic Non-Small Cell Lung Cancer: Exposure-Response Relationship

Published Date: July 16, 2022

Prognostic and predictive factors in patients with advanced HCC and elevated alpha-fetoprotein treated with ramucirumab in two randomized Phase III trials

Published Date: April 20, 2022

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

Published Date: April 6, 2022

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

Published Date: March 28, 2022

The exposure-response relationship of ramucirumab in the RANGE randomized phase III trial of patients with advanced urothelial carcinoma refractory to platinum therapy

Published Date: January 13, 2022

Published Date: January 3, 2022

RELAY: Clinical and Next-Generation Sequencing Analyses of Ex19del and Ex21L858R Mutation Subgroups in Untreated, EGFR-Mutated, Metastatic Non-small Cell Lung Cancer

Published Date: January 3, 2022

A multicenter, double-blind, randomized phase III trial of ramucirumab plus docetaxel versus placebo plus docetaxel for treatment of Stage IV non-small cell lung cancer after disease progression on or after platinum-based therapy (REVEL): An Indian patient subgroup analysis

Published Date: January 1, 2022

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW-Asia): a double-blind, randomised phase 3 trial

Published Date: October 7, 2021

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)

Published Date: August 25, 2021

Clinical Development and Evaluation of a VEGF-D Assay in Plasma from Patients with Metastatic Colorectal Cancer in the RAISE Study

Published Date: July 28, 2021

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.

Published Date: June 29, 2021

Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology

Published Date: June 26, 2021

Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study

Published Date: May 25, 2023

Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer

Published Date: May 17, 2023

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer.

Published Date: April 27, 2023

Real-world Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States

Published Date: February 23, 2023

Risk Thresholds for Patients to Switch Between Daily Tablets and Biweekly Infusions in Second-Line Treatment for Advanced Hepatocellular Carcinoma: a Patient Preference Study

Published Date: January 19, 2023

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Published Date: December 12, 2022

Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis.

Published Date: February 23, 2022

Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm+ NSCLC

Published Date: October 12, 2021

Erbitux^® (cetuximab)

Full Prescribing Information

No Publication Journals

Efficacy and safety of cetuximab dosing (biweekly vs weekly) in patients with KRAS wild-type metastatic colorectal cancer: A meta-analysis.

Published Date: February 19, 2022

No Publication Journals

Inluriyo^™ (imlunestrant)

Full Prescribing Information

Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open-Label Study.

Published Date: June 24, 2025

Identification of a Safe and Tolerable Carbamazepine Dosing Paradigm that Facilitates Effective Evaluation of CYP3A4 Induction.

Published Date: June 10, 2024

Phase 1 Study Evaluating the Effect of Food and Omeprazole-Induced Gastric pH Change on the Pharmacokinetics and Safety of Imlunestrant in Healthy Females.

Published Date: November 21, 2025

Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: results from the phase 1a/1b EMBER study

Published Date: October 22, 2024

Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.

Published Date: December 21, 2025

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.

Published Date: October 7, 2024

No Publication Journals

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Published Date: December 13, 2024

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial

Published Date: December 12, 2025

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial

Published Date: April 1, 2025

No Publication Journals

Jaypirca^® (pirtobrutinib)

Full Prescribing Information

Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial.

Published Date: February 28, 2025

Phase 1/2 BRUIN Trial Results of Pirtobrutinib Monotherapy in BTK Inhibitor Intolerant Patients with B-cell Malignancies

Published Date: January 6, 2025

Evaluation of Bleeding Risk in Patients Who Received Pirtobrutinib in the Presence or Absence of Antithrombotic Therapy

Published Date: September 27, 2024

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.

Published Date: July 18, 2024

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.

Published Date: July 6, 2023

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.

Published Date: May 16, 2023

Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor

Published Date: February 17, 2023

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTK Inhibitor in Relapsed Marginal Zone Lymphoma: Phase 1/2 BRUIN Study

Published Date: January 17, 2026

Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Published Date: October 8, 2025

Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial.

Published Date: February 28, 2025

Phase 1/2 BRUIN Trial Results of Pirtobrutinib Monotherapy in BTK Inhibitor Intolerant Patients with B-cell Malignancies

Published Date: January 6, 2025

Evaluation of Bleeding Risk in Patients Who Received Pirtobrutinib in the Presence or Absence of Antithrombotic Therapy

Published Date: September 27, 2024

Published Date: July 18, 2024

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.

Published Date: July 6, 2023

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.

Published Date: May 16, 2023

Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor

Published Date: February 17, 2023

Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

Published Date: February 11, 2026

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Published Date: December 9, 2025

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Published Date: December 7, 2025

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Published Date: June 6, 2025

BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor Naïve mantle cell lymphoma.

Published Date: November 15, 2022

Real-world treatment patterns, patient characteristics, and outcomes of initial cBTKi-based therapies in second-line or later amongst a contemporary cohort of patients with MCL in the United States

Published Date: February 24, 2026

Continuity of care for patients with chronic lymphocytic leukemia: an analysis of real-world data

Published Date: September 15, 2025

Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study

Published Date: September 9, 2025

Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States

Published Date: August 7, 2025

Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Published Date: March 23, 2025

Clinical trial participation, clinical care, and patient outcomes by practice setting: a real-world database analysis of patients with Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma

Published Date: February 5, 2025

Racial and Ethnic Characteristics and Outcomes of Patients Diagnosed with CLL/SLL in the USA

Published Date: May 28, 2024

Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study

Published Date: April 16, 2023

Outcomes Among Patients with Mantle Cell Lymphoma post-covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study

Published Date: December 28, 2022

Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study

Published Date: November 8, 2022

Retevmo^® (selpercatinib)

Full Prescribing Information

Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Solid Tumors.

Published Date: May 15, 2025

Long-term Safety of Selpercatinib for RET-activated Advanced Solid Tumors in LIBRETTO-001

Published Date: November 15, 2024

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.

Published Date: August 2, 2024

Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial

Published Date: May 14, 2024

Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001

Published Date: December 27, 2023

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer.

Published Date: May 18, 2023

Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

Published Date: September 19, 2022

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.

Published Date: September 15, 2021

NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.

Published Date: September 15, 2021

Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase 1/2 LIBRETTO-001Trial

Published Date: September 13, 2021

Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Solid Tumors.

Published Date: May 15, 2025

Long-term Safety of Selpercatinib for RET-activated Advanced Solid Tumors in LIBRETTO-001

Published Date: November 15, 2024

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.

Published Date: August 2, 2024

Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial

Published Date: May 14, 2024

Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001

Published Date: December 27, 2023

Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial.

Published Date: June 15, 2023

Selpercatinib Monotherapy for RET Fusion/EGFR Co-Mutated Non-Small Cell Lung Cancer: A Case from the Phase II LIBRETTO-321 Study in Chinese Patients

Published Date: June 4, 2023

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer.

Published Date: May 18, 2023

Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

Published Date: September 19, 2022

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

Published Date: September 12, 2022

Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)

Published Date: September 6, 2022

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.

Published Date: September 15, 2021

Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase 1/2 LIBRETTO-001Trial

Published Date: September 13, 2021

Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer | Thyroid®

Published Date: October 10, 2025

First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion-Positive NSCLC: A LIBRETTO-431 Subgroup Analysis.

Published Date: July 21, 2025

Patient-Reported Outcomes (PROs) from LIBRETTO-431: First-Line Selpercatinib versus Chemotherapy With Pembrolizumab in RET Fusion-positive NSCLC

Published Date: June 17, 2025

Selpercatinib in Chinese patients with RET-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the randomized LIBRETTO-321 phase II trial

Published Date: January 1, 2025

CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.

Published Date: June 3, 2024

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

Published Date: October 21, 2023

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

Published Date: October 21, 2023

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-Naïve RET-mutant medullary thyroid cancer.

Published Date: August 15, 2022

LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer

Published Date: August 11, 2022

Real-World Outcomes of Selective RET Inhibitor Selpercatinib in the United States: Descriptive, Retrospective Findings from Two Databases

Published Date: November 15, 2024

Initial versus early switch to targeted therapy during first-line treatment among patients with biomarker-positive advanced or metastatic non-small cell lung cancer in the United States

Published Date: September 12, 2023

Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.

Published Date: March 20, 2023

Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study.

Published Date: December 8, 2022

Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021

Published Date: August 15, 2022

Diagnostic Value and Cost-Effectiveness of Next Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer in the United States.

Published Date: July 28, 2022

Full article: Biomarker Testing in Patients Diagnosed With Advanced/Metastatic Medullary Thyroid Cancer in the USA

Published Date: May 10, 2022

Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer

Published Date: February 12, 2022

Verzenio^® (abemaciclib)

Full Prescribing Information

Published Date: November 4, 2025

A Phase 1 study of abemaciclib plus abiraterone in Japanese patients with metastatic castration-resistant prostate cancer

Published Date: September 9, 2025

Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study

Published Date: March 12, 2025

Abemaciclib does not increase the corrected QT interval in healthy participants.

Published Date: June 26, 2023

Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study

Published Date: November 5, 2022

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.

Published Date: February 10, 2022

Abemaciclib in Combination with Pembrolizumab for Stage IV KRAS-Mutant or Squamous Non-Small Cell Lung Cancer: A Phase 1B Study

Published Date: September 24, 2021

Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Published Date: October 27, 2025

A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.

Published Date: March 29, 2024

Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial.

Published Date: December 14, 2023

Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant vs trastuzumab plus chemotherapy in HR+, HER2+ metastatic breast cancer patients

Published Date: October 31, 2023

Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer

Published Date: October 27, 2023

An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer

Published Date: August 1, 2022

nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer

Published Date: July 12, 2022

Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Published Date: October 27, 2025

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH trial

Published Date: October 18, 2025

Overall survival with abemaciclib in early breast cancer.

Published Date: October 17, 2025

Abemaciclib Plus Fulvestrant in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Final Overall Survival Results From MONARCH 2

Published Date: August 5, 2025

Survival benefit from abemaciclib in non-small cell lung cancer by Kirsten rat sarcoma-mutation gene expression subtype: retrospective analysis from the JUNIPER Trial.

Published Date: March 31, 2025

Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase 3 randomized monarchE study

Published Date: October 23, 2024

Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial.

Published Date: October 10, 2024

The Impact of Dose Reductions on Efficacy of Adjuvant Abemaciclib for Patients with High-Risk Early Breast Cancer: Analyses from the monarchE Study

Published Date: April 26, 2024

Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer - European Journal of Cancer

Published Date: January 16, 2024

Adjuvant abemaciclib plus endocrine therapy for high-risk, HR+, HER2-, early breast cancer: results from a preplanned monarchE overall survival.

Published Date: January 9, 2024

Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count with Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial

Published Date: November 16, 2023

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.

Published Date: February 8, 2023

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Published Date: December 6, 2022

Adjuvant Abemaciclib Combined with Endocrine Therapy (ET): Efficacy Results in monarchE Cohort 1

Published Date: November 7, 2022

Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.

Published Date: October 14, 2022

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.

Published Date: June 2, 2022

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.

Published Date: June 1, 2022

Safety in Japanese advanced breast cancer patients who received abemaciclib in MONARCH 2 and MONARCH 3: assessment of treatment-emergent neutropenia, diarrhea, and increased alanine aminotransferase and aspartate aminotransferase levels

Published Date: March 19, 2022

Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.

Published Date: January 31, 2022

A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone.

Published Date: January 26, 2022

Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Published Date: October 18, 2021

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.

Published Date: October 14, 2021

Abemaciclib plus fulvestrant in hormone receptor positive, HER2-negative advanced breast cancer in premenopausal and perimenopausal women: a subgroup analysis from MONARCH 2 trial

Published Date: August 23, 2021

MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2- advanced breast cancer

Published Date: August 9, 2021

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

Published Date: June 22, 2021

Abemaciclib Persistence in Patients with HR+, HER2−, Node-Positive Early Breast Cancer: a Real-World Analysis | Oncology and Therapy

Published Date: September 22, 2025

Full article: Costs of breast cancer recurrence after initial treatment for HR+, HER2−, high-risk early breast cancer: estimates from SEER-Medicare linked data

Published Date: December 19, 2023

Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice | Drugs - Real World Outcomes

Published Date: August 16, 2023

Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world

Published Date: June 14, 2023

Characteristics and Outcomes in US Male Patients (Pts) with Metastatic Breast Cancer (MBC) Receiving Abemaciclib (Abema) in Routine Clinical Practice

Published Date: April 2, 2023

Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database

Published Date: November 21, 2022

Real-world patient characteristics, utilization patterns, and outcomes of US patients with HR+/HER2- metastatic breast cancer treated with abemaciclib

Published Date: September 22, 2022

A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer

Published Date: May 25, 2022

Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.

Published Date: May 10, 2022

Adjuvant Abemaciclib Combined With Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study

Published Date: March 22, 2022

Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.

Published Date: March 1, 2022

Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study.

Published Date: November 3, 2021

Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review

Published Date: August 20, 2021

Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2− advanced breast cancer patients with poor prognostic factors: data from an international study

Published Date: August 7, 2021

Can't find what you're looking for? Contact us for answers to your medical questions.

Copyright
Terms of Use
Privacy Statement
Consumer Health Privacy Notice
Accessibility Statement
Sitemap

This site is intended for US Healthcare Professionals only.

Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

Your Privacy Choices

Cookie Settings

Oncology Journal Publications

Cyramza: Phase I Phase I

Cyramza: Phase II Phase II

Cyramza: Phase III Phase III

Cyramza: Phase IV & Real World Evidence Phase IV & Real World Evidence

Erbitux: Phase I (No Publications Available) Phase I (No Publications Available)

Erbitux: Phase II (No Publications Available) Phase II (No Publications Available)

Erbitux: Phase III Phase III

Erbitux: Phase IV & Real World Evidence (No Publications Available) Phase IV & Real World Evidence (No Publications Available)

Inluriyo<sup>™</sup> (imlunestrant) Publications : Phase I Phase I

Inluriyo<sup>™</sup> (imlunestrant) Publications : Phase II (No Publications Available) Phase II (No Publications Available)

Inluriyo<sup>™</sup> (imlunestrant) Publications : Phase III Phase III

Inluriyo<sup>™</sup> (imlunestrant) Publications : Phase IV (No Publications Available) Phase IV (No Publications Available)

Jaypirca: Phase I Phase I

Jaypirca: Phase II Phase II

Jaypirca: Phase III Phase III

Jaypirca: Phase IV & Real World Evidence Phase IV & Real World Evidence

Retevmo: Phase I Phase I

Retevmo: Phase II Phase II

Retevmo: Phase III Phase III

Retevmo: Phase IV & Real World Evidence Phase IV & Real World Evidence

Verzenio: Phase I Phase I

Verzenio: Phase II Phase II

Verzenio: Phase III Phase III

Verzenio: Phase IV & Real World Evidence Phase IV & Real World Evidence